SITE NEWS

New IceMD Recording:

Studies Show Fruits and Veggies Reduce Cancer;

   Dow Stock News

Hewlett-Packard Co. (HPQ) agreed to acquire Israeli inkjet printer maker NUR Macroprinters Ltd. for $117.5 million. The Palo Alto, Calif., computer company said the deal expands its graphic arts portfolio of digital presses and wide-format printers. Hewlett-Packard posted 2007 revenue of about $104.3 billion. - MarketWatch

McDonald's Corp., the world's No. 1 hamburger chain, said Monday global same-store sales rose 8.2 percent in November. Same-store sales, or sales at restaurants open at least thirteen months, is a key indicator of retailer performance since it measures growth at existing restaurants rather than newly opened ones. In the U.S., same-store sales rose 4.4 percent, boosted by sales of coffee, breakfast items and Dollar Menu selections. In Europe, same-store sales grew 10.8 percent, helped by sales of premium burgers and chicken products in Germany, the U.K. and France. In Asia/Pacific, Middle East and Africa, same-store sales rose 12 percent on strong sales in Japan, Australia and China, McDonald's said. - AP

Barron's writes that JP Morgan (JPM) has done better than most banks in the current debt crisis and should do unusually well going forward.

Reuters reports that the Citigroup (C) board will meet early this week to consider a new CEO.

   Ice Man Stocks

Breakouts the Ice Man may consider trading:

DEP 24.40

Regular Trades the Ice Man may consider:

VNDA 9.20
TMA 11.80 Bid
YGE 32.50 = 35 Gap
GVA Above 41.75
NCTY Above 25.75
LLNW Above 8.10
GA Above 13.20 Bid to 14.80 Gap
USU Above 9 Bid
PCS Above 18 Bid
CBL Above 29.10
GGC Above 8.85
SNTS Above 2.80
IAR Above 19
OC Above 23.30
BUNT 14 Bid
TRMP Above 5.65
CMI Above 1.28

   Media Commentators

Cramer's Comments:

Bullish: DE, MON, BG, MOS, AGU, POT, NYX, MUHLX;

Barrons:

Negative comments on Yahoo while they say MSFT and GOOG are thriving.
Positive comments on PALM.

   Ice Cold Commentators

Break Man Video Summary:

Break out buy (or short sell) watch list for short term gains December 10 includes:  PGI, COWN, ESEA, LRW, PSPT, OFG, JFR, OLN, GHDX, FMER, CLR, RNT.

Several candidates for break out or short sell  plays for at least short term gains by buying the break out (or selling the break down) on good volume and closing at least some on the  first day.

Swing Man Market Recap:

The market advanced higher again this week as it continues its move up off the bottom.  After a two day pullback on Monday and Tuesday, which held above the pivot support at 1462 on the SPX, the market moved to new highs for this rally.  The SPX/DOW gained 1.75% for the week while the NDX/NAZ added 1.85%.  The SPX has now gained close to 100 points off the recent lows.  The government reacted to the housing crisis on Thursday with a five year rate freeze on adjustable rate mortgages established between 2005 and July of 2007 which served to lesson the impact from the mortgage/credit crisis.  As a result, stocks had their best day of the week on the news.  Next week, the focus will turn to the Federal Reserve meeting on tap for Tuesday afternoon.  Expectations are for a rate cut of at least ¼ point on both the federal funds rate and the discount rate.

After breaking out of a falling bullish wedge pattern on Wednesday of the previous week, the SPX found resistance two days later (Friday) at the 1490 level.  The SPX pulled back from this resistance level on Monday and Tuesday which created the right shoulder of an inverse head and shoulders pattern (see 60 minute chart below).  On Thursday, the SPX broke thru resistance (neckline at 1490) and closed the week nicely above this pivot level.  Although nothing is certain, the objective measurement from this pattern of the SPX would call for a target of at least 1460 over time.  Should the SPX elect to pullback from current levels, the index should now find support at the 1490 level.  

After the close on Thursday, I pointed out that many of the major indexes were at/near resistance and overbought on their intraday charts.  The market action on Friday can best be described as a day of consolidation following a strong two day rally.  Short term momentum is beginning to ease back after reaching overbought levels at Thursday´s close.  On Friday´s trading session, the intraday charts of the major indexes began to form lateral/slightly down bullish flag patterns which allow for some unwinding on the oscillators with minimal price giveback.  As previously mentioned above, the SPX 1490 area should provide good support on further selling.  The Nasdaq 15 minute chart currently displays a small triangle with initial support at 2695 followed by additional support near the 2675 area.

Good Trading.

   CNBC Fast Money Review

1. STOCKS JUMP 2% AHEAD OF FED

The headline: S&P 500, Dow Average Climb 2% This Week Ahead of Fed Meeting Next Week
Jeff Macke says think investors should buy the S&P, set a stop at 1495, “grab a pair’ and go for it.
Karen Finerman added  There are not a lot of things left to go wrong and there are a lot of things left that could go right.
Pete Najarian thinks there are problems “out there’ in hedge-fund land. CORS is a great example of a stock with too much short interest for Pete´s comfort level.

2. SEMI GOOD WEEK

The headline: INTC, MU, RMBS, Semiconductor Stocks Break Out This Week.
Pete Najarian explains Thomas Weisel upgraded Intel Wednesday, citing growing global demand for laptops. However, his favorite tech name remains AAPL.

3. RATE CUTS 'ROUND THE WORLD

The headline: Global Markets Surge This Week as Rate Cuts Catch On.
Karen Finerman explains the Bank of England cut key rates Thursday by quarter-point. It´s the 1st reduction in 2 years. She adds it´s good for the US because it gives the Fed more room to cut. And, she adds, copper is down 15% in the past 2 or 3 months – which could be a sign of inflation coming down. That also would give the Fed room to cut.
Jeff Macke agrees.
Guy Adami says The dollar might have turned – going into ´08 – long dollar could be the trade. And if I had to go into emerging markets CHL is my play.
Pete Najarian prefers agriculture names such as MON as his global play.

4. THE BROTHERS GRIM?

LEH kicks off broker earnings Thursday before the bell. Will the credit crunch drag down their numbers?
Karen Finerman says long GS and short LEH. I think there is bad news coming out of Lehman. Thursday is a chance for them to come clean on their subprime exposure.
Guy Adami agrees. He anticipates that Lehman shares will drop.
Pete Najarian explains that he will watch options action closely early in the week before he makes a LEH trade.

5. BLOOD ON THE STREET

What´s the biotech trade as the American Society Of Hematology Conference kicks off in Atlanta?
Pete Najarian says AMGN, DNA, BIIB, CELG, and CEPH are all presenting at the conference. PHRM was just bought by Celgene and if they present information suggesting drugs in their pipeline are successful, these stocks could move higher.
Also, MLNM has some late stage drugs – which could be attractive to PZE. Pete thinks PFE could be “sniffing around’ the conference looking for a takeover target.

6. POPS AND DROPS FOR THE WEEK

ATVI popped 21%. The videogame maker soared all week after it agreed to sell a controlling stake to Vivendi, creating the world's largest videogame maker.
COST popped 7%. The wholesaler's same-store sales increased 9% and beat analysts´ estimates.
IMAX popped 56%. The operator of giant- screen movie theaters had its biggest gain ever after it announced plans to install 100 digital projection systems in AMC Theatres. Jeff Macke says Sell this pop.
RAD popped 9%: Guy Adami recommends owning it.
CMCSA dropped 11%: Guy Adami thinks the stock is a buy if it drops another 50 cents.
MBI dropped 18%: Karen Finerman says It´s a bear story.
PALM dropped 17%: Pete Najarian said the stock has a real problem.

7. YOR FIRST MOVE FOR MONDAY

Guy Adami recommends MSFT.
Karen Finerman prefers PLCE.
Pete Najarian says TGT is a buy.
Jeff Macke didn't have a stock.

   News and Events Digest

Breaking News

UBS said Singapore's foreign-reserves fund and another investor injected $11.5 billion as part of a broader move to strengthen capital as the Swiss bank announced a further $10 billion in write-downs on subprime holdings. - WSJ
Nokia Siemen Networks (NOK), (SI) Monday said China Mobile Group Beijing Ltd. (CHL) has selected Nokia Siemens Networks to expand its General Packet Radio Services, or GPRS, core network. - MarketWatch

Agrium Inc. (AGU), said Monday it'll sell $1.25 billion in its common shares in Canada and the U.S. The Calgary-based agricultural products firm said it'll use proceeds from the sale to fund a portion of the purchase price of its previously announced cash tender offer for all of the outstanding shares of common stock of UAP Holding Corp. - MarketWatch

GE Healthcare, a unit of General Electric Co., and biotech drug developer Novavax Inc. said Monday they have agreed to partner to develop and market an avian flu vaccine system for certain countries. - AP

China TechFaith Wireless Communication Technology Limited (CNTF) an original design product (ODP) provider focused on research and development of cell phone solutions, today announced the further expansion of its global reach into the Indian market. The first contract is on mid to high-end CDMA 1X long standby feature phones awarded by an Indian operator brand. First shipment of the product is expected in the first quarter of 2008.

Media Summary

According to Reuters, UBS (UBS) will writes down about $10 billion in subprime financial instrument and raise new capital from sources including the Singapore government.

Reuters reports that Blackstone (BX) is preparing a bid for Rio Tinto (RTP) One of the investors would be a financial arm of the Chinese government.

Reuters reports that The International Herald Tribune, a part of The New York Times (NYT) will begin to carry Reuters news in its business section.

The Wall Street Journal writes that the NY Attorney General and SEC looked into Bear Stearns (BSC) valuation of mortgage securities iin 2005, but dropped the probe.

The Wall Street Journal writes that big social network Imeem has entered into an agreement which will allow is users to listen to Univeral Music songs for free.

The Wall Street Journal writes that Iran has signed a deal with Chinese oil company Sinopec to develop a key field in the Middle Eastern country.

The New York Times writes that Nokia (NOK) is trying to increase it share of the US handset market.

The New York Time writes that Yahoo! (YHOO) will start an internet video channel for technology investors.

The New York Times write that he $60 billion Qatar Investment Authority is looking for more big investment opportunities in US banks.

The FT writes that China has raised the level of investment allowed by foreign firms to $30 billion.

Bloomberg writes that Societe General will take on $4.3 billion in SIVs to prevent a fire sale.

M&A Activity:

Evraz Group S.A. said Monday it'll buy Claymont Steel Holdings Inc. (PTLE) for $23.50 a share for an aggregate price of approximately $565 million, including debt and net of cash. The offer price represents a premium of 19.1% to Claymont Steel's three month volume weighted average stock price, a premium of 38.2% to Claymont Steel's IPO price of $17.00 in December, 2006, and a premium of 6.8% to the closing price of Claymont Steel's stock on Friday. - MarketWatch

Reckitt Benckiser Group said Monday that it has offered to buy Adams Respiratory Therapeutics (ARXT) for $60 a share, or $2.3 billion, in cash. Adams is a specialty pharmaceutical company, headquartered in Chester, New Jersey, and is exclusively focused on the development, commercialisation and marketing of pharmaceuticals for the treatment of respiratory disorders. "Adams will add to our portfolio a new, rapidly growing powerbrand in Mucinex, a market and innovation leader in cough and congestion relief in the U.S. Equally important, it will provide Reckitt Benckiser an entry into health care in the U.S.," said Reckitt CEO Bart Becht. The deal is expected to be immediately earnings enhancing for Reckitt Benckiser, excluding a $60m one restructuring charge. - MarketWatch

Eisai Co Ltd. said on Monday it would buy U.S. biotech firm MGI Pharma Inc. (MOGN) for $3.9 billion cash to strengthen its cancer treatment pipeline, marking the largest overseas acquisition by a Japanese drug maker. - Reuters

IPO Central:

IPOs on schedule for the week of 12/10/07:

BGMedicine (BGMD). The company is a life sciences company focused on the development and commercialization of molecular diagnostics based on biomarkers. The company is selling 4.5M shares at the initial range between $14-$16. The company announced Revenues for the last 12 months of $9M and Net Income of $(-6)M. The Lead Manager is Cowen and Leerink is Co. Manager. BGMedicine (BGMD) is headquartered in Waltham, MA and the company website is www.bg-medicine.com.

Cardtronics (CATM). The company owns and operates 12,000 automated teller machines (ATMs) throughout the United States. The company is selling 16.7M shares at the initial range between $14-$16. The company announced Revenues for the last 12 months of $546M and Net Income of $3M. The Lead Managers are Deutsche Bank, William Blair, and Bank of America. Cardtronics (CATM) is headquartered in Houston, TX and the company website is www.cardtronics.com.

CampusU (CMPS). The company is an online merchandising/marketing/media company focused on the college student market. The company is selling 3.5M shares at the initial range between $5.5-$6.50. The company announced Revenues for the last 12 months of $12M and Net Income of $(-6)M. The Lead Manager is Maxim Group. CampusU (CMPS) is headquartered in Leesburg, VA
and the company website is www.CampusUInc.com.

CGEN Digital Media Company Limited (ADTV). The company Operates one of the largest in-store television advertising networks in China. The company is selling 9.2M shares at the initial range between $13-$15. The company announced Revenues for the last 12 months of $33M and Net Income of $8M. The Lead Manager is Piper Jaffray and Jefferies is Co. Manager. CGEN Digital Media Company Limited (ADTV) is headquartered in Shanghai, China and the company website is www.cgenmedia.cn.

ChinaEdu Corporation (CEDU). The company is a leading Chinese educational services provider to online degree programs. The company is selling 6.8M shares at the initial range between $10-$12. The company announced Revenues for the last 12 months of $31M and Net Income of $3M. The Lead Manager is Bear Stearns and Piper Jaffray is Co. Manager. ChinaEdu Corporation (CEDU) is headquartered in Beijing, China and the company website is www.chinaedu.net.

Economic Data:

10:00 Pending Home Sales

   Upgrades and Downgrades by Sector:

Airlines - Passenger
 AKH Air France KLM UBS Upgraded from Neutral to Buy
 RYAAY Ryanair Hldgs UBS Upgraded from Neutral to Buy

Audio-Video Equipmnt
 GMST Gemstar-TV Guide Morgan Joseph Upgraded from Hold to Buy $5.95
 EMR Emerson Deutsche Securities Downgraded from Buy to Hold
 GMST Gemstar-TV Guide Kaufman Bros Downgraded from Buy to Hold $8 to $6

Biotech
 LIFC LifeCell Banc of America Sec Initiated at Neutral
 AMGN Amgen Bernstein Downgraded from Outperform to Mkt Perform
 SGXP SGX Pharma JMP Securities Downgraded from Mkt Outperform to Mkt Perform

Business Services
 CRN Cornell Corr Lehman Brothers Upgraded from Underweight to Equal-weight
 DCP Dyncorp Intl Wachovia Upgraded from Mkt Perform to Outperform
 DCP Dyncorp Intl Jefferies & Co Upgraded from Hold to Buy

Computer Hardware
 NICE CIBC Says to Buy Here
 PALM Palm UBS Downgraded from Neutral to Sell

Computer Services
 RATE Bankrate Citigroup Upgraded from Hold to Buy

Computer Software
 PRFT Perficient Roth Capital Upgraded from Hold to Buy $20
 RHT Red Hat Jefferies & Co Downgraded from Buy to Hold $23 to $19

Construction
 TEX Terex UBS Upgraded from Neutral to Buy
 MLM Martin Marietta UBS Initiated at Neutral
 MTRX Matrix Service Co KeyBanc Capital Mkts Initiated at Hold
 VMC Vulcan Materials UBS Initiated at Sell

Educational Services
 ESI ITT Educational Lehman Brothers Upgraded from Equal-weight to Overweight
 LTRE Learning Tree Stifel Nicolaus Downgraded from Buy to Hold

Healthcare
 ABAX Abaxis Sun Trust Rbsn Humphrey Price Target Raised Buy $28 to $42
 TRIB Trinity Biotech Roth Capital Price Target Raised Buy $11.50 to $10.50
 RTIX Regeneration Tech Banc of America Sec Initiated at Buy $13
 SKH Skilled Healthcare Credit Suisse Initiated at Outperform $18

Healthcare - Labs
 GXDX Genoptix Lehman Brothers Initiated at Overweight
 GXDX Genoptix Banc of America Sec Initiated at Buy $36

Healthcare Equipment
 EW Edwards Lifesci Credit Suisse Price Target Raised Outperform $61 to $62

Industrial Metals
 PVG Penn Va GP Hldgs JP Morgan Initiated at Overweight

Insurance
 NYM Nymagic Fox Pitt Upgraded from In Line to Outperform
 HNT Health Net Credit Suisse Initiated at Neutral $53

Manufacturing
 BEC Beckman Coulter Banc of America Sec Upgraded from Neutral to Buy

Motion Pictures
 MVSN Macrovision Jefferies & Co Price Target Raised Hold $28 to $23

Oil and Gas
 RIG Transocean Friedman Billings Price Target Raised Outperform $140 to $172
 PVA Penn Virginia JP Morgan Initiated at Overweight
 STO StatoilHydro Deutsche Securities Downgraded from Buy to Hold
 GSF GlobalSantaFe Friedman Billings Coverage Dropped

Personal Services
 SCI Service Corp JP Morgan Initiated at Overweight
 STEI Stewart Enterpr JP Morgan Initiated at Neutral

Real Estate
 PVR Penn Virginia JP Morgan Initiated at Overweight

REITs
 DRE Duke Realty Friedman Billings Price Target Raised Mkt Perform $40 to $32
 AMC Amer Mort Accept RBC Capital Mkts Downgraded from Sector Perform to Underper

Retail Trade
 CC Circuit City Soleil Upgraded from Hold to Buy $13
 FDO Family Dollar Credit Suisse Price Target Raised Neutral $28 to $18
 TGT Target Credit Suisse Price Target Raised Outperform $66 to $64
 FRED Fred's JP Morgan Initiated at Neutral

Semiconductors
 NVLS Merrill Lynch Upgraded to Buy

Solar Energy
 FSLR First Solar Credit Suisse Resumed Coverage Outperform $250

Telecommunications
 MBT Mobile TeleSystems Lehman Brothers Initiated at Overweight
 SMLC 012 Smile.Communications Cowen & Co Initiated at Outperform
 SMLC 012 Smile.Communications CIBC Wrld Mkts Initiated at Sector Outperform $16
 VIP Vimpel Comms Lehman Brothers Initiated at Overweight
 PT Portugal Telecom Credit Suisse Downgraded from Outperform to Underperform
 TKG Telkom SA Deutsche Securities Downgraded from Buy to Hold

Transportation
 FWRD Forward Air Bear Stearns Downgraded from Peer Perform to Underperform

Utilities
 D Dominion Credit Suisse Downgraded from Outperform to Neutral $49
 VE Veolia Environnement Brean Murray Downgraded from Buy to Hold

_______________________

Asian Fund Info:

On November 11/14/07, Sansar Capital Management filed a 13G showing that they purchased a 5.18% position (2,438,685 shares) in Eternal Technologies (ETLT). This is a major fund that invests in promising Asian Firms. Sansar has taken major positions in these Chinese companies over the last two years and made huge returns.  Here are just some of their recent holdings:

WuXI PharmaTech - Symbol: WX    411,835 shares (investment nearly tripled)
GigaMedia – Symbol: GIGM   4,659,724 shares (purchased between $2.00-8.00 per share and sold all shares recently)
Asiainfo Holdings Inc.  Symbol: ASIA   2,339,408 shares (purchased between $3.00-4.00 per share and sold all shares recently)

This group has made many more purchases in Asian stocks (including India) and made HUGE GAINS. They get in when they see value and sell for large profits over time similar to what Miguel has done.
 

Neuralstem Coverage:

Wall Street Grand Report
 
I am pleased to announce that our new 5 Star stock is NEURALSTEM Inc trading on the AMEX under ticker symbol CUR.

I want to state right now that I believe CUR will be the #1 leading stem cell company in the industry.
 
CUR closed Friday at $2.82 and only has a current valuation of $84.7 Million.
 
In my opinion, I feel CUR is a huge opportunity for the investment community and one that will be very rewarding.
 
CUR is financially solid with $9 Million in cash and NO DEBT!
 
When compared to other “peer’ stem cell companies CUR has a much undervalued valuation. For instance, STEM has a market cap of $154 Million, OSIR has a market cap of $360 Million, and GERN has a market cap of $541 Million.
 
I believe CUR has much bigger potential than all 3 of these companies and only has a market cap of $84.7 Million!
 
There has been a lot of controversial debate when the subject of “stem cells’ is brought up but lets face it, stem cells are the future for pharmaceutical industry. The fact of the matter is stem cell technology will save lives one day.
 
I think CUR is the perfect opportunity to capitalize on this revolutionary market.
 
CUR is Biopharmaceutical Company whose mission is to apply stem cell research and its patented human neural stem cell technology to treat diseases of the central nervous system including Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS ( Lou Gehrig's disease) and Parkinson´s Disease.
  
Right now, no effective treatments exist for debilitating CNS (Central Nervous System) disorders.
 
An estimated 50 Million Americans of all ages suffer from nervous system disorders like neurodegenerative diseases and traumatic injury, and the population grows each year. These conditions can dramatically reduce the patient's quality of life and cost society hundreds of BILLIONS of dollars annually for medical expenses and lost productivity! More than 600 disorders of the nervous system have been identified, including common diseases like stroke, epilepsy, muscular dystrophy, Parkinson's disease, multiple sclerosis, traumatic spinal cord injury, and autism.
 
Most degenerative disorders occur when nerve cells, or neurons lose function. Since neurons cannot regenerate spontaneously, this degeneration often leads to chronic, debilitating and potentially lethal outcomes for patients. Again let me reiterate there are NO effective treatments exist for most nervous system indications.
  
CUR is the first company to use stem cell technology to treat nervous system disorders.
  
I am not a doctor but I will do my best in explaining how CUR is doing this. If you do not understand something please feel free to contact me and if I can't give you the answer I will get you in touch with someone at the company who can.
  
The nervous system is a complex organ that includes the central nervous system (CNS) consisting of the brain and spinal cord, and the peripheral nervous system (PNS) comprised of the nerves throughout the rest of the body. The "PNS" consists of 33 nerve bundles branching through the body, with junctions at the spinal cord permitting them to convey motor and sensory impulses to the "CNS."
 
The Nervous System
  
The CNS is composed of cells called neurons, which carry impulses, and glial cells called astrocytes and oligodendrocytes that surround and provide support to the neurons. Neurons basically affect all aspects of behavior including thought and movement.
 
Neuron w/ supporting Glial Cells
 
A loss of these neuronal cells, as a result, can cause significant impairment of nervous system function and lead to chronic, debilitating conditions with potentially lethal consequences for patients.
  
CUR is using their new patent protected process to grow neural stem cells for the treatment of diseases in the CNS (Central Nervous System). Their technology allows them to produce mature, commercial quantities of neural stem cells with the ability to control the differentiation of the cells into physiologically relevant human neurons and glia. These neural stem cells can replicate themselves up to as many as 60 generations creating up to a BILLION-BILLION cells!
  
I would like everyone to please watch this video on CUR's website to explain how they have used their patented stem cell technology to fix ischemic paraplegia! Here's the link: http://www.neuralstem.com/index.asp?pgid=14
  
CUR has amassed a considerable bank of neural stem cells derived from a single donor tissue, composed of cells from every important area of the CNS. According to management, approximately 1 MILLION individual neural stem cell "doses", consisting of all important cell types, have been accumulated and stored by the company!!!
  
What's amazing about that is they have enough neural stem cells  to support all anticipated pre-clinical investigations in various CNS indications, and forthcoming human clinical trials and potential commercialization!!!
  
No other stem cell company has what CUR has! On top of that CUR has already stated that they done tests with paralyzed rats and with their technology have proven to help the rats walk again and extend their life!
 
Neural Stem Cells
  
"These stem cells not only survived in an extremely adverse environment, but may have actually produced and delivered motor neuron growth factors, which promote growth and function, to the sick motor neurons," stated by Vassillis E. Koloatsos, whose lab conducted the study!
  
While other studies have reported only limited success with spinal cord-injured rats, "we made them walk again," said CUR's scientific founder and Chairman, Karl Johe. " We do expect the same thing in humans but it is more complicated."
  
He even stated that he thinks it would have worked for actor Christopher Reeves!
  
The reason why I feel this is the perfect time to get in is because not only did they successfully make paralyzed rats walk again but they announced that they expect to file for their first IND ( Investigational New Drug) for Human trials to the FDA by the end of 2007! That's this month!
  
The IND will be for Ischemic Paraplegia that sometimes results from complications in the repair of aortic aneurysms. CUR also expects to follow this in 2008 with an IND for traumatic spinal cord injury, and a 3rd IND for ALS. Again there are NO effective treatments for any of these indications!
  
What is completely unique about CUR's trials compared to other stem cell companies is that other companies trials for embryonic stem cells have proven to be significantly challenging with many technical hurdles while CUR's neural stem cell trials have overcome these issues demonstrating excellent safety and tolerability combined with potent efficacy in pre-clinical studies.
  
Also, unlike other stem cell companies CUR will know immediately in phase 1 trails if their technology works or not. From my understanding, CUR is involving actual nerve-damaged patients in their Phase 1 trials, not healthy volunteers enrolled only to measure the treatment's safety. This way even though Phase 1 is just to determine if the process is safe, it will also prove right off the bat if a patient shows signs of improvement in movement. If one of these paralyzed patients show improvement in their motor skills, CUR will be the #1 talk in the news!
 
We will have results by early 2008! If everything goes well the stock could go up ten-fold!
  
In the meantime, please take some time to research CUR. It is unbelievable what they have accomplished. Here is a link to their website: http://www.neuralstem.com/index.asp?pgid=1

_____________________

My new stock to watch with a speculative rating of 1 is: Neuralstem Inc. (CUR). It closed this week at $2.82 and it trades on the AMEX.

CUR could be the biggest money maker of your life-time!

CUR is the only company in the world that I believe has the potential to cure paralyzed humans and make them walk again. The company has already helped paralyzed rats walk again.

CUR uses patent-protected technology that allows them to produce neural stem cells with the ability to control the differentiation of the cells into physiologically relevant human neurons and glia. Once approved by the FDA, these cells could be transplanted into humans as treatments for currently incurable diseases.

CUR's recently completed pre-clinical studies have dispelled the notion that spinal neurons cannot be repaired or restored.

CUR found that stem cells in the state of "limbo" could be tricked into maintaining rapid division if exposed to specific factors and mediums that interrupt the internal "code" limiting self-renewal.

CUR has already amassed a bank of neural stem cells at Charles River Laboratories capable of providing up to one million doses in humans.

By the end of December, CUR is expected to file their first ever Investigational New Drug (IND) application with the FDA. The first IND will be for the treatment of Ischemic Paraplegia, a form of paraplegia that sometimes results from complications in the repair of aortic aneurysms.

CUR expects to begin Phase 1 trials for Ischemic Paraplegia in early 2008!

CUR also expects to file a second IND for Traumatic Spinal Cord Injury in the first half of 2008 and begin Phase 1 trials for Traumatic Spinal Cord Injury in the second half of 2008.

In late 2008, CUR expects to file a third IND for ALS (also known as Lou Gehrig´s disease).

Check out this article that came out about CUR one week ago in the Maryland Gazette: http://www.gazette.net/stories/113007/polinew54413_32379.shtml

Pay particular attention to the last sentence in the article where it says that CUR's CEO Richard Garr, "expects to sign an overseas partner before the first trial to develop markets in Asia."

With CUR's IND for Ischemic Paraplegia expected this month and Phase 1 trials expected to begin in early 2008, it is possible we could hear news about this potential partner in Asia very soon!

CUR finished last quarter with $5.3 million in cash and on October 26th they received another $3.4 million in cash from the exercise of warrants. This means CUR is probably now sitting on close to $9 million in cash with practically no debt.

CUR has been able to keep their overhead low with a very small burn rate by outsourcing their research and development to numerous universities.

CUR's Ischemic Paraplegia treatments are being developed at the University of South Florida. CUR's Traumatic Spinal Cord Injury treatments are being developed at John Hopkins University. CUR's ALS treatments are being developed at the University of Michigan.

CUR will be using actual nerve-damaged patients in their Phase 1 trials, not healthy volunteers. By giving real doses to real patients, the effects of CUR's stem cell treatments will be seen very early!

Check out this video right now on CUR's web site... showing how they will be doing stem cell transplantation: http://www.neuralstem.com/index.asp?pgid=14

Exactly one year ago today, I announced another stem cell stock PSTI as one of my top 5 picks for 2007 at $3.30 and just a few months later it hit $30.80.

Remember... I have given CUR a speculative rating of 1, my highest level of confidence. My last eight stocks to watch with a speculative rating of 1 have gained an average of 119% at their highs from my pick price!

Please do your own research and don't make investment decisions based on anything I say. Past performance is not an indicator of future returns.